

Heart failure

Due to various possible causes, blood moves through the heart and body at a slower rate, and pressure in the heart increases. As a result, the heart cannot pump enough [oxygen](#) and [nutrients](#) to meet the body's needs. The chambers of the heart may respond by stretching to hold more blood to pump through the body or by becoming stiff and thickened. This helps to keep the blood moving, but the heart muscle walls may eventually weaken and become unable to pump as efficiently. As a result, the kidneys may respond by causing the body to retain fluid (water) and salt. If fluid builds up in the arms, legs, ankles, feet, lungs, or other organs, the body becomes congested, and congestive heart failure is the term used to describe the condition.

Neurosurgery

- [Prevalence, Pathophysiology, and Prognostic Importance of Malnutrition Risk in Early-Stage Patients With Heart Failure and Preserved Ejection Fraction](#)
- [Hemoglobin decline within 24 h post-mechanical thrombectomy as an indicator of poor clinical outcomes](#)
- [Characteristics and outcomes in patients with in-hospital stroke: Japan Stroke Data Bank](#)
- [Innovation under pressure: Managing a complex carotid-jugular fistula in a war-zone limited-resources area](#)
- [A prospective clinical trial predicting the 95% effective concentration of remifentanyl for skull pin fixation using haemodynamic and surgical pleth index monitoring](#)
- [Management of non-Cardiac Organ Failure in cardiogenic shock](#)
- [Pathophysiological and Prognostic Importance of an ExtraCardiac Comorbidity Burden in Patients with Heart Failure with Preserved Ejection Fraction](#)
- [Alzheimer's Disease With Cardiac Transthyretin Amyloidosis: A Clinicopathological Study of Autopsy Cases](#)

[Mitigation](#) of cardiac [autonomic dysregulation](#) by [neuromodulation](#) technologies is emerging as a new therapeutic [modality](#) of [heart failure](#) (HF). This [progress](#) has necessitated the [identification](#) of a [biomarker](#) for the [quantification](#) of sympathovagal [balance](#), the potential target of 'neuromodulation' strategies. The currently available [autonomic nervous system](#) assessment parameters do not truly reflect the sympathovagal balance of the [ventricle](#). [Protein kinase A](#) (PKA) is an intracellular enzyme that plays a major role in the [pathophysiology](#) of functional and structural ventricular remodeling in HF. Interestingly, sympathetic and parasympathetic activations exert reciprocal [influence](#) on the [activity](#) of PKA ¹⁾.

¹⁾
Chakraborty P, Po SS, Yabluchanskiy A, Dasari TW. [Protein kinase A](#): A potential [marker](#) of sympathovagal [imbalance](#) in [heart failure](#). Life Sci. 2023 Sep 2;122069. doi: 10.1016/j.lfs.2023.122069. Epub ahead of print. PMID: 37666387.

From:

<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**

Permanent link:

https://neurosurgerywiki.com/wiki/doku.php?id=heart_failure

Last update: **2024/06/07 02:51**

